The organization implored nations to wait on booster shots until the global vaccination rate increases, but several of the world’s more well-off countries have expressed their intentions to offer them regardless.

A study looks beyond T and B cell responses to show how the Pfizer COVID-19 vaccine elicits a strong innate immune response.

Scientists at the US CDC report no red flags in a preliminary analysis of the safety of Pfizer/BioNTech’s and Moderna’s mRNA-based immunizations among expectant mothers.

The chance of developing cerebral venous sinus thrombosis was nearly 10 times higher in the two weeks following a diagnosis of SARS-CoV-2 infection than after receiving an mRNA vaccine, a data analysis finds.

In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

Johnson & Johnson’s one-shot immunization could reach people’s arms as early as March 2.

Two preliminary reports from the UK provide real-world evidence in support of the Pfizer/BioNTech and Oxford-AstraZeneca vaccines.

Preliminary results from an Israel-based study suggest that one dose of the vaccine reduces infectiousness—a key factor in slowing virus spread.

Johnson & Johnson’s vaccine is less effective at preventing COVID-19 than other approved vaccines are, but experts say it could still be an important tool in curbing the pandemic.

Vaccine experts say the results surpass their expectations, but the study is not complete, and the data have not been peer reviewed.

Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.

An exploration of the genetics of earlobe attachment is just the latest collaborative research project to come out of the personal genetic testing company.

The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.

Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.

The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.

A move by the US federal government to close tax loopholes that encourage “tax inversions” likely spooked the companies out of the multibillion dollar deal.

The two drugmakers will join forces in a $160 billion deal—if it’s given the regulatory green light.